Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Bone and Mineral Metabolism
Published in: Journal of Bone and Mineral Metabolism 4/2019

01-07-2019 | Original Article

RETRACTED ARTICLE: Effect of RAB31 silencing on osteosarcoma cell proliferation and migration through the Hedgehog signaling pathway

Authors: Qiong Yu, Dong Li, Dan Wang, Chun-Mei Hu, Yan Sun, Yan Tang, Guang Shi

Published in: Journal of Bone and Mineral Metabolism | Issue 4/2019

Login to get access

Abstract

Osteosarcoma (OS) is a prevalent cancer that plagues people worldwide. Identifying prognostic markers would be useful in treating human OS. In this study, we aimed to explore the functions of Ras-related protein Rab-31 (RAB31) in OS-cell proliferation, migration, and invasion as well as its roles in the Hedgehog signaling pathway for better understanding of the mechanism. To assess the detailed regulatory mechanism of RAB31 silencing on OS, both RT-qPCR and Western blot analysis were employed to evaluate the expressions of RAB31 as well as the Hedgehog signaling pathway-related genes. Besides, we also investigated the effects of silenced RAB31 both in vitro and in vivo. First, we found that in OS tissues, both mRNA and protein expressions of RAB31 and PCNA had a significant increase. Second, the Hedgehog signaling pathway was detected to play an integral role in OS progression. Finally, after transfection of RAB31-siRNA to reduce the expression of RAB31, the Hedgehog signaling pathway was suppressed, along with cell proliferation, invasion, and migration. Therefore, we conclude that RAB31 plays an important role in OS development and its silencing delays the OS progression via suppression of the Hedgehog signaling pathway.
Literature
1.
Liu T, Zhou W, Zhang F, Shi G, Teng H, Xiao J, Wang Y (2014) Knockdown of IRX2 inhibits osteosarcoma cell proliferation and invasion by the AKT/MMP9 signaling pathway. Mol Med Rep 10:169–174CrossRef
2.
Luetke A, Meyers PA, Lewis I, Juergens H (2014) Osteosarcoma treatment—where do we stand? A state of the art review. Cancer Treat Rev 40:523–532CrossRef
3.
Savage SA, Mirabello L (2011) Using epidemiology and genomics to understand osteosarcoma etiology. Sarcoma 2011:548151CrossRef
4.
Huang J, Ni J, Liu K, Yu Y, Xie M, Kang R, Vernon P, Cao L, Tang D (2012) HMGB1 promotes drug resistance in osteosarcoma. Cancer Res 72:230–238CrossRef
5.
Mirabello L, Pfeiffer R, Murphy G, Daw NC, Patino-Garcia A, Troisi RJ, Hoover RN, Douglass C, Schuz J, Craft AW, Savage SA (2011) Height at diagnosis and birth-weight as risk factors for osteosarcoma. Cancer Causes Control 22:899–908CrossRef
6.
Wang Y, Li L, Shao N, Hu Z, Chen H, Xu L, Wang C, Cheng Y, Xiao J (2015) Triazine-modified dendrimer for efficient TRAIL gene therapy in osteosarcoma. Acta Biomater 17:115–124CrossRef
7.
Bienemann K, Staege MS, Howe SJ, Sena-Esteves M, Hanenberg H, Kramm CM (2013) Targeted expression of human folylpolyglutamate synthase for selective enhancement of methotrexate chemotherapy in osteosarcoma cells. Cancer Gene Ther 20:514–520CrossRef
8.
Xu M, Xu SF, Yu XC (2014) Clinical analysis of osteosarcoma patients treated with high-dose methotrexate-free neoadjuvant chemotherapy. Curr Oncol 21:e678–684CrossRef
9.
Oertel S, Blattmann C, Rieken S, Jensen A, Combs SE, Huber PE, Bischof M, Kulozik A, Debus J, Schulz-Ertner D (2010) Radiotherapy in the treatment of primary osteosarcoma—a single center experience. Tumori J 96:582–588CrossRef
10.
Chua CE, Tang BL (2015) The role of the small GTPase Rab31 in cancer. J Cell Mol Med 19:1–10CrossRef
11.
Chua CE, Tang BL (2014) Engagement of the small GTPase Rab31 protein and its effector, early endosome antigen 1, is important for trafficking of the ligand-bound epidermal growth factor receptor from the early to the late endosome. J Biol Chem 289:12375–12389CrossRef
12.
Grismayer B, Solch S, Seubert B, Kirchner T, Schafer S, Baretton G, Schmitt M, Luther T, Kruger A, Kotzsch M, Magdolen V (2012) Rab31 expression levels modulate tumor-relevant characteristics of breast cancer cells. Mol Cancer 11:62CrossRef
13.
Jin C, Rajabi H, Pitroda S, Li A, Kharbanda A, Weichselbaum R, Kufe D (2012) Cooperative interaction between the MUC1-C oncoprotein and the Rab31 GTPase in estrogen receptor-positive breast cancer cells. PLoS One 7:e39432CrossRef
14.
Serao NV, Delfino KR, Southey BR, Beever JE, Rodriguez-Zas SL (2011) Cell cycle and aging, morphogenesis, and response to stimuli genes are individualized biomarkers of glioblastoma progression and survival. BMC Med Genom 4:49CrossRef
15.
Chan LH, Wang W, Yeung W, Deng Y, Yuan P, Mak KK (2014) Hedgehog signaling induces osteosarcoma development through Yap1 and H19 overexpression. Oncogene 33:4857–4866CrossRef
16.
Briscoe J, Therond PP (2013) The mechanisms of Hedgehog signalling and its roles in development and disease. Nat Rev Mol Cell Biol 14:416–429CrossRef
17.
Pan Y, Zhang Y, Chen L, Liu Y, Feng Y, Yan J (2016) The Critical Role of Rab31 in Cell Proliferation and Apoptosis in Cancer Progression. Mol Neurobiol 53:4431–4437CrossRef
18.
Cao CM, Yang FX, Wang PL, Yang QX, Sun XR (2014) Clinicopathologic significance of S100A4 expression in osteosarcoma. Eur Rev Med Pharmacol Sci 18:833–839PubMed
19.
20.
Vergara-Lluri ME, Moatamed NA, Hong E, Apple SK (2012) High concordance between HercepTest immunohistochemistry and ERBB2 fluorescence in situ hybridization before and after implementation of American Society of Clinical Oncology/College of American Pathology 2007 guidelines. Mod Pathol 25:1326–1332CrossRef
21.
Warzecha J, Gottig S, Chow KU, Bruning C, Percic D, Boehrer S, Brude E, Kurth A (2007) Inhibition of osteosarcoma cell proliferation by the Hedgehog-inhibitor cyclopamine. J Chemother 19:554–561CrossRef
22.
Li S, Sun W, Wang H, Zuo D, Hua Y, Cai Z (2015) Research progress on the multidrug resistance mechanisms of osteosarcoma chemotherapy and reversal. Tumour Biol 36:1329–1338CrossRef
23.
Yamamoto N, Tsuchiya H (2013) Chemotherapy for osteosarcoma—where does it come from? What is it? Where is it going? Expert Opin Pharmacother 14:2183–2193CrossRef
24.
Yang D, Liu G, Wang K (2015) miR-203 acts as a tumor suppressor gene in osteosarcoma by regulating RAB22A. PLoS One 10:e0132225CrossRef
25.
Shahi MH, Holt R, Rebhun RB (2014) Blocking signaling at the level of GLI regulates downstream gene expression and inhibits proliferation of canine osteosarcoma cells. PLoS One 9:e96593CrossRef
26.
Hirotsu M, Setoguchi T, Sasaki H, Matsunoshita Y, Gao H, Nagao H, Kunigou O, Komiya S (2010) Smoothened as a new therapeutic target for human osteosarcoma. Mol Cancer 9:5CrossRef
27.
Wang W, Luo H, Wang A (2006) Expression of survivin and correlation with PCNA in osteosarcoma. J Surg Oncol 93:578–584CrossRef
28.
29.
Wang D, Bi Z (2014) Bufalin inhibited the growth of human osteosarcoma MG-63 cells via down-regulation of Bcl-2/Bax and triggering of the mitochondrial pathway. Tumour Biol 35:4885–4890CrossRef
30.
Wuichet K, Sogaard-Andersen L (2014) Evolution and diversity of the Ras superfamily of small GTPases in prokaryotes. Genome Biol Evol 7:57–70CrossRef
31.
Warzecha J, Dinges D, Kaszap B, Henrich D, Marzi I, Seebach C (2012) Effect of the Hedgehog-inhibitor cyclopamine on mice with osteosarcoma pulmonary metastases. Int J Mol Med 29:423–427PubMed
32.
Paget C, Duret H, Ngiow SF, Kansara M, Thomas DM, Smyth MJ (2012) Studying the role of the immune system on the antitumor activity of a Hedgehog inhibitor against murine osteosarcoma. Oncoimmunology 1:1313–1322CrossRef
33.
Saitoh Y, Setoguchi T, Nagata M, Tsuru A, Nakamura S, Nagano S, Ishidou Y, Nagao-Kitamoto H, Yokouchi M, Maeda S, Tanimoto A, Furukawa T, Komiya S (2016) Combination of Hedgehog inhibitors and standard anticancer agents synergistically prevent osteosarcoma growth. Int J Oncol 48:235–242CrossRef
34.
Ding YL, Zhou Y, Xiang L, Ji ZP, Luo ZH (2012) Expression of glioma-associated oncogene homolog 1 is associated with invasion and postoperative liver metastasis in colon cancer. Int J Med Sci 9:334–338CrossRef
35.
Tao Y, Mao J, Zhang Q, Li L (2011) Overexpression of Hedgehog signaling molecules and its involvement in triple-negative breast cancer. Oncol Lett 2:995–1001PubMedPubMedCentral
36.
You S, Zhou J, Chen S, Zhou P, Lv J, Han X, Sun Y (2010) PTCH1, a receptor of Hedgehog signaling pathway, is correlated with metastatic potential of colorectal cancer. Ups J Med Sci 115:169–175CrossRef
37.
Sui Y, Zheng X, Zhao D (2015) Rab31 promoted hepatocellular carcinoma (HCC) progression via inhibition of cell apoptosis induced by PI3K/AKT/Bcl-2/BAX pathway. Tumour Biol 36:8661–8670CrossRef
38.
Lo WW, Wunder JS, Dickson BC, Campbell V, McGovern K, Alman BA, Andrulis IL (2014) Involvement and targeted intervention of dysregulated Hedgehog signaling in osteosarcoma. Cancer 120:537–547CrossRef
39.
Eggenschwiler JT, Espinoza E, Anderson KV (2001) Rab23 is an essential negative regulator of the mouse Sonic hedgehog signalling pathway. Nature 412:194–198CrossRef
Metadata
Title
RETRACTED ARTICLE: Effect of RAB31 silencing on osteosarcoma cell proliferation and migration through the Hedgehog signaling pathway
Authors
Qiong Yu
Dong Li
Dan Wang
Chun-Mei Hu
Yan Sun
Yan Tang
Guang Shi
Publication date
01-07-2019
Publisher
Springer Singapore
Published in
Journal of Bone and Mineral Metabolism / Issue 4/2019
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-018-0961-9

Other articles of this Issue 4/2019

Journal of Bone and Mineral Metabolism 4/2019 Go to the issue

Original Article

Screening of key candidate genes and pathways for osteocytes involved in the differential response to different types of mechanical stimulation using a bioinformatics analysis

Original Article

Cortical bone mineral density is increased by the cathepsin K inhibitor ONO-5334, which leads to a robust increase in bone strength: results from a 16-month study in ovariectomised cynomolgus monkeys

Original Article

Overweight and underweight are risk factors for vertebral fractures in patients with type 2 diabetes mellitus

Original Article

miR-195 contributes to human osteoarthritis via targeting PTHrP

Original Article

Quantitation and distribution of metallic elements in sequestra of medication-related osteonecrosis of jaw (MRONJ) using inductively coupled plasma atomic emission spectroscopy and synchrotron radiation X-ray fluorescence analysis

Original Article

Lycopene influences osteoblast functional activity and prevents femur bone loss in female rats submitted to an experimental model of osteoporosis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits